VolitionRx publishes corporate deck outlining Nu.Q licensing strategy in cancer, sepsis diagnostics

VolitionRX Ltd

VolitionRX Ltd

VNRX

0.00
  • VolitionRx highlighted an asset-light strategy focused on licensing Nu.Q technology across cancer and NETosis/sepsis applications, targeting multiple human-health licensing deals in 2025 and 2026.
  • Commercial update centered on animal-health licensing, citing $23 million in licensing to date and revenue of $1 million in Q1 2026.
  • Near-term catalyst flagged as expected publication of a feline study, positioned to unlock a contractual milestone payment of $5 million.
  • Pipeline milestones included DETECSEPs tracking to first patient enrollment in Q3 2026, reimbursement submission work underway, and initial EU sales growth focus for a CE-marked NETosis/sepsis product.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief on May 15, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.